Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor

A Phase I Study of Allogeneic NK Cell Therapy in Patients With Refractory/Relapsed Lymphoma or Solid Tumor

Allogeneic natural killer (NK) cells (MG4101) were manufactured from normal healthy donor who underwent leukapheresis. These cells were processed based on a novel method for ex vivo activation and expansion using an irradiated and activated autologous feeder cell system. MG4101 has anti-tumor activities against various tumors including malignant lymphomas in vitro as well as in vivo tumor model.

Inclusion Criteria:

• Age 18 years or older
• Histologically or cytologically confirmed malignant lymphoma or solid tumor
• After the failure of standard treatment
• KPS >70 or ECOG PS 0-2
• Adequate bone marrow, renal, and liver functions
• Expected survival at least 3 months
• Informed consent

Exclusion Criteria:

• Pregnancy or lactating woman
• HIV patients
• Prior exposure to cell-based therapy
• Hypersensitivity to interleukin-2
• Patients with autoimmune disease